Khurram Jamil - Aug 2, 2024 Form 3 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Aug 2, 2024
Transactions value $
$0
Form type
3
Date filed
8/5/2024, 08:38 AM
Previous filing
Aug 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GALT Common Stock Option (right to buy) Aug 2, 2024 Common Stock 150K $2.20 Direct F1, F2
holding GALT Restricted Stock Unit Aug 2, 2024 Common Stock 30K $0.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock Options were granted to the Reporting Person by the Issuer in connection with his employment as vice president clinical development and medical director in March 2024 prior to his appointment as Chief Medical Officer by the Board of Directors. The options are exercisable in three equal traches on March 11, 2025, March 11, 2026, and March 11, 2027.
F2 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F3 Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.
F4 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.